Syndax Pharmaceuticals Inc
A biopharmaceutical company in Waltham, Massachusetts, Syndax makes two FDA-approved cancer therapies: Revuforj, a first-in-class menin inhibitor for certain acute leukemias, and Niktimvo, an antibody for chronic graft-versus-host disease after bone-marrow transplants. Founded in 2005 with help from a Salk Institute scientist, it launched both drugs in 2024, the year it became a commercial-stage company. Its coined name is thought to blend scientific innovation with its business aims.
Bought 150.0K
Granted 1.24M · Sold 755.0K
Granted 361.7K · Bought 14.0K · Sold 136.4K
Granted 144.1K · Bought 4.3K · Sold 12.3K
Granted 148.0K · Bought 10.0K · Sold 34.0K
Granted 221.0K · Sold 107.0K
Granted 114.0K
Granted 98.0K · Bought 5.0K
Granted 173.0K · Sold 83.0K
Granted 89.7K · Sold 4.6K
Granted 113.8K · Bought 11.8K · Sold 65.5K
Granted 49.0K
Granted 1.20M · Bought 43.9K · Sold 1.11M
Granted 85.5K · Sold 53.5K
Granted 9.4K · Bought 708
Granted 113.2K · Sold 119.0K
Sold 968
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Foley Todd +9 co-filers10% owner · 3 transactions | — | 5.16Mas of Mar 2016 | — | — | — |
| Evnin LukeDirector, 10% owner · 3 transactions | — | 1.86Mas of Mar 2016 | — | — | — |
| Blair James C +4 co-filers10% owner · 1 transaction | — | 1.74Mas of Mar 2016 | — | — | — |
| Blair James C +5 co-filers10% owner · 1 transaction | — | 761.1Kas of Mar 2016 | — | — | — |
| Royston IvorDirector · 5 transactions | — | 625.5Kas of Mar 2017 | — | 150.0K | — |
| Metzger Michael AChief Executive Officer, Director · 70 transactions | — | 484.8K | 1.24M | — | 755.0K |
| Biotechnology Value Fund II LP +6 co-filersSee Explanation of Responses, 10% owner · 3 transactions | — | 318.0Kas of Jun 2018 | — | — | — |
| Podlesak DennisDirector · 20 transactions | — | 239.8K | 361.7K | 14.0K | 136.4K |
| Goldan Keith A.Chief Financial Officer · 20 transactions | — | 139.3K | 144.1K | 4.3K | 12.3K |
| Katkin KeithDirector · 23 transactions | — | 124.0K | 148.0K | 10.0K | 34.0K |
| Legault PierreDirector · 20 transactions | — | 114.0K | 221.0K | — | 107.0K |
| Jarrett JenniferDirector · 6 transactions | — | 114.0K | 114.0K | — | — |
| Huber Martin H. Jr.Director · 6 transactions | — | 103.0K | 98.0K | 5.0K | — |
| Meury WilliamDirector · 11 transactions | — | 90.0Kas of Feb 2025 | 173.0K | — | 83.0K |
| Gallagher NeilPresident, Head of R&D · 5 transactions | — | 85.1Kas of Feb 2025 | 89.7K | — | 4.6K |
| Botwood Nicholas A.J.Head of R&D, CMO · 7 transactions | — | 60.9K | 113.8K | 11.8K | 65.5K |
| Rizo AleksandraDirector · 2 transactions | — | 49.0K | 49.0K | — | — |
| Morrison BriggsDirector · 50 transactions | — | 34.8Kas of Feb 2024 | 1.20M | 43.9K | 1.11M |
| Egros FabriceDirector · 16 transactions | — | 32.0Kas of Feb 2022 | 85.5K | — | 53.5K |
| Meyers Michael L.SVP, Chief Medical Officer · 9 transactions | — | 23.3Kas of Jan 2022 | 9.4K | 708 | — |
| Blair James C +4 co-filers10% owner, Director, 10% owner · 1 transaction | — | 13.9Kas of Mar 2016 | — | — | — |
| Shea Richard PChief Financial Officer · 3 transactions | — | 7.1Kas of Jan 2020 | — | — | — |
| Blair James C +5 co-filers10% owner · 1 transaction | — | 5.6Kas of Mar 2016 | — | — | — |
| Ordentlich PeterChief Scientific Officer · 28 transactions | — | 0as of Feb 2023 | 113.2K | — | 119.0K |
| Nolte AlexanderChief Accounting Officer · 2 transactions | — | 0as of Feb 2022 | — | — | 968 |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over all recorded history: -2.24M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.